TCF1/TCF7 (C63D9) Rabbit mAb (Pacific Blue™ Conjugate)

LEF1 and TCF are members of the high mobility group (HMG) DNA-binding protein family of transcription factors that consists of the following: Lymphoid Enhancer Factor 1 (LEF1), T Cell Factor 1 (TCF1/TCF7), TCF3/TCF7L1, and TCF4/TCF7L2 (1). LEF1 and TCF1/TCF7 were originally identified as important factors that regulate early lymphoid development (2) and act downstream in Wnt signaling. LEF1 and TCF bind to Wnt response elements to provide docking sites for β-catenin, which translocates to the nucleus to promote the transcription of target genes upon activation of Wnt signaling (3). LEF1 and TCF are dynamically expressed during development and aberrant activation of the Wnt signaling pathway is involved in many types of cancers, including colon cancer (4,5).TCF1/TCF7 has several isoforms due to alternative splicing and transcription from an alternative promoter. The isoforms generated by the alternative promoter do not contain the amino-terminal β-catenin binding domain and therefore may function in a dominant negative manner (6). TCF1/TCF7 displays dynamic expression both in the total amount and the type of isoforms expressed in T cells during development and differentiation (7). 1.Waterman, M.L. (2004) Cancer Metastasis Rev 23, 41-52. 2.Schilham, M.W. and Clevers, H. (1998) Semin Immunol 10, 127-32. 3.Brantjes, H. et al. (2002) Biol Chem 383, 255-61. 4.Reya, T. and Clevers, H. (2005) Nature 434, 843-50. 5.Logan, C.Y. and Nusse, R. (2004) Annu Rev Cell Dev Biol 20, 781-810. 6.Waterman, M.L. (2004) Cancer Metastasis Rev 23, 41-52. 7.Willinger, T. et al. (2006) J Immunol 176, 1439-46.